Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCharmacy Phar
Stock Code02289
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是華南地區領先的醫藥分銷商之一,主要於中國分銷藥品,向醫藥分銷商客戶、零售藥店及醫院、診所、衛生站及其他分銷醫藥產品,亦向供應商提供營銷策略諮詢服務及有關信息服務。
Listing Date2015-12-14
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)廣東省汕頭市龍湖區嵩山北路235號
Business Address (Hong Kong)香港灣仔皇后大道東28號金鐘滙中心18樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitechmyy.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 8.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2015-12-02 to 2015-12-07
Global Offering Shares28,000,000 shares
HK Public Offer Shares (Initial)2,800,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)25,200,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO108,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share10.5%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 240,800,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 599.5M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1520%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣36.4百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2012201320142015-06
Revenue 2,016,9432,401,2313,014,0591,635,397
Cost of sales -1,929,662-2,297,253-2,877,618-1,551,784
Gross profit 87,281103,978136,44183,613
Other income and gains, net 4,4054,9955,2452,818
Selling and distribution expenses -22,385-25,137-35,757-18,504
Administrative expenses -29,076-33,972-37,162-22,674
Operating profit 40,22549,86468,76745,253
Net finance costs -19,660-20,550-22,832-11,538
Profit before tax 20,56529,31445,93533,715
Income tax expense -6,454-7,095-9,490-8,481
Profit for the year 14,11122,21936,44525,234
Profit attributable to owners 14,11122,21936,44525,234
Balance Sheet
Item 2012201320142015-06
Cash and cash equivalents 12,34616,76122,29624,702
Trade and bills receivables 543,298721,210864,395979,627
Inventories 210,856256,746244,935242,087
Total current assets 950,9731,239,9991,336,9721,521,389
Total assets 1,163,0591,444,6021,533,9361,712,816
Total current liabilities 976,1581,235,4821,288,3711,472,017
Total liabilities 976,1581,235,4821,288,3711,472,017
Total equity 186,901209,120245,565240,799
Equity attributable to owners 186,901209,120245,565240,799
Interest-bearing borrowings 258,494299,560301,350278,750
Cash Flow Statement
Item 2012201320142015-06
Net cash from operating activities 61,70045,104-14,826134,379
Net cash from investing activities -104,218-61,70540,903-67,835
Net cash from financing activities 41,85421,016-20,542-64,138
Net increase in cash -6644,4155,5352,406
Depreciation of PP&E 7,0639,9679,7254,411
Amortisation of intangible assets 2,2152,2152,2151,108
Purchase of PP&E -41,833-5,104-4,447-497
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 8.0
First Day OpenHK$ 7.7
First Day Change-6.98%
First Day Volume8018500.0
First Day Turnover64439800.0
Use of Proceeds
1、約64.8百萬港元(約35%)將用于增強、擴展及整合我們現存的分銷網絡及能力; 2、約18.5百萬港元(約10%)將用于改良及推廣我們的B2B電子商務平臺; 3、約55.6百萬港元(約30%)將用于償還銀行借款; 4、約27.8百萬港元(約15%)將用于收購華南地區的醫藥分銷業務; 5、約18.5百萬港元(約10%)用于營運資金及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Bookrunners (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Lead Managers (3)
国泰君安证券(香港)有限公司 CE ABY236 EVER-LONG SECURITIES COMPANY LIMITED CE ACM423 LUK FOOK SECURITIES (HK) LIMITED CE ACU547

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 广药白云山香港有限公司 67,995,900 HKD — 7.30% — 6 months 2016-06-14
2 香雪集团(香港)有限公司 29,996,800 HKD — 3.20% — 6 months 2016-06-14

Directors & Management

PositionChinese nameEnglish Name
Chairman姚創龍—
Company Secretary林志雄、吳詠珊—
No director data available.

Major Shareholders

Major Shareholders & Holdings姚先生(董事會主席)實益持有70,000,000股內資股(87.5%),配偶權益1,000,000股(1.25%);游澤燕女士(配偶)持有配偶權益及受控法團權益;姚女士(姚先生之母)實益持有6,500,000股內資股(8.125%)。上市後姚先生及游澤燕女士各約65.74%,姚女士約6.01%。
About this page

This page shows Charmacy Phar (02289) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect